Suppr超能文献

年轻早期交界性卵巢肿瘤患者的子宫卵巢保存与总体生存。

Utero-ovarian preservation and overall survival of young women with early-stage borderline ovarian tumors.

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Los Angeles County Medical Center, University of Southern California, 2020 Zonal Avenue, IRD520, Los Angeles, CA, 90033, USA.

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

出版信息

Arch Gynecol Obstet. 2019 Jun;299(6):1651-1658. doi: 10.1007/s00404-019-05121-z. Epub 2019 Mar 28.

Abstract

PURPOSE

To examine survival of women who had uterine and ovarian preservation during surgical treatment for early-stage borderline ovarian tumors (BOTs).

METHODS

The Surveillance, Epidemiology, and End Results Program was used to identify women aged < 50 years with stage I BOTs who underwent ovarian conservation at surgical treatment between 1988 and 2003. Survival outcomes were examined based on the use of concurrent hysterectomy at surgery.

RESULTS

Among 6379 cases of BOT, there were 1065 women who had utero-ovarian preservation at surgery, and there were 52 women who had hysterectomy with ovarian preservation alone. Women who had uterine preservation were more likely to be single and diagnosed in recent years (both, P < 0.05). On univariable analysis, women who had utero-ovarian preservation had cause-specific survival similar to those who had ovarian preservation alone without uterine preservation (10-year rates: 99.2% versus 98.1%, P = 0.42); however, overall survival was higher in the utero-ovarian preservation group compared to the hysterectomy group (95.8% versus 87.6%, P < 0.001). On multivariable analysis, utero-ovarian preservation remained an independent prognostic factor for improved overall survival (adjusted hazard ratio 0.35, 95% confidence interval 0.15-0.79, P = 0.012). Cardiovascular disease mortality was lower in the utero-ovarian preservation group compared to the hysterectomy group, but it did not reach statistical significance (20-year cumulative rate, 0.8% versus 3.0%, P = 0.29).

CONCLUSION

Our study suggests that utero-ovarian preservation for young women with early-stage BOTs may be associated with improved overall survival compared to ovarian preservation alone without affecting BOT-related survival outcome.

摘要

目的

研究在手术治疗早期交界性卵巢肿瘤(BOT)期间行子宫和卵巢保留术的女性的生存情况。

方法

利用监测、流行病学和最终结果计划(Surveillance, Epidemiology, and End Results Program),确定 1988 年至 2003 年期间手术治疗时行卵巢保留术且年龄<50 岁的 I 期 BOT 患者。基于手术时是否同时行子宫切除术,评估生存结局。

结果

在 6379 例 BOT 中,有 1065 例患者行子宫-卵巢保留术,52 例患者仅行保留卵巢的子宫切除术。保留子宫的患者更可能是单身且近年诊断(两者,P<0.05)。单变量分析显示,行子宫-卵巢保留术的患者与未行子宫切除而仅行卵巢保留术的患者的肿瘤特异性生存率相似(10 年生存率:99.2%比 98.1%,P=0.42);然而,子宫-卵巢保留组的总生存率高于子宫切除术组(95.8%比 87.6%,P<0.001)。多变量分析显示,子宫-卵巢保留术仍是改善总生存率的独立预后因素(调整后的危险比为 0.35,95%置信区间为 0.15-0.79,P=0.012)。与子宫切除术组相比,子宫-卵巢保留组的心血管疾病死亡率较低,但差异无统计学意义(20 年累积发生率,0.8%比 3.0%,P=0.29)。

结论

本研究表明,与仅行卵巢保留术相比,年轻的早期 BOT 患者行子宫-卵巢保留术可能与总生存率的提高相关,而不会影响 BOT 相关的生存结局。

相似文献

引用本文的文献

1
Fertility preservation in women with benign gynaecological conditions.患有良性妇科疾病女性的生育力保存
Hum Reprod Open. 2023 Apr 6;2023(2):hoad012. doi: 10.1093/hropen/hoad012. eCollection 2023.

本文引用的文献

2
Staging for low malignant potential ovarian tumors: a global perspective.低恶性潜能卵巢肿瘤的分期:全球视角
Am J Obstet Gynecol. 2016 Aug;215(2):153-168.e2. doi: 10.1016/j.ajog.2016.04.035. Epub 2016 Apr 27.
4
Controversies in borderline ovarian tumors.卵巢交界性肿瘤中的争议
J Gynecol Oncol. 2015 Oct;26(4):343-9. doi: 10.3802/jgo.2015.26.4.343. Epub 2015 Sep 23.
8
Borderline ovarian tumors: features and controversial aspects.交界性卵巢肿瘤:特征与争议点。
Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):86-9. doi: 10.1016/j.ejogrb.2012.11.002. Epub 2012 Dec 5.
9
Diagnosis, treatment, and follow-up of borderline ovarian tumors.交界性卵巢肿瘤的诊断、治疗和随访。
Oncologist. 2012;17(12):1515-33. doi: 10.1634/theoncologist.2012-0139. Epub 2012 Sep 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验